Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

NCT05974410 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Glioblastoma
Squamous Cell Carcinoma
Hodgkin Lymphoma
Non-hodgkin Lymphoma
Breast Cancer
Prostate Cancer
Gastric Cancer
Ovarian Cancer
Acute Leukemia
Pancreatic Cancer
Spindle Cell Sarcoma
Cancer
Tumor, Solid
Tumor, Brain
Esophageal Andeocarcinoma
Mixed Phenotype AML
Desmoplastic Round Cell Sarcoma

Interventions

DRUG: AVM0703
DRUG: Hydrocortisone
DRUG: Proton pump inhibitor

Sponsor

AVM Biotechnology Inc